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6 the receptor, has been used to treat spasticity for more than 30 years. Ongoing screening efforts in the pharmaceutical industry using the recombinant GABA B R are aimed at expanding the range of receptor selective drugs (Marshall, 2005) .
Cumulative evidence suggests that agonist stimulation of a GPCR triggers a transition from the inactive to the active receptor state leading to the induction of second messenger signaling (Gether, 2000) . Even in the absence of agonist, however, many GPCRs exhibit a limited degree of ligand-independent (constitutive) signaling that is determined by the equilibrium between active and inactive conformations of the receptor (Adan and Kas, 2003) . Constitutive activity of a given GPCR can be increased by introduction of receptor point mutations that further favor the active state. The vast majority of constitutively active receptors are "partially on" (i.e. stimulation with agonist leads to a further shift toward the active state and an increase in second messenger signaling).
Stimulation with agonist and induction of mutation-induced ligand-independent signaling offer complementary approaches to probe the mechanisms underlying receptor activation.
Although activating point mutations have been described for many GPCRs, none has been reported for heterodimeric receptors, leading to the question of whether there are fundamental differences between homo-and heterodimeric receptors.
In the studies described here, we demonstrate that selected single amino acid substitutions in either GABA B R subunit result in significant constitutive activity of the heterodimers formed from an association of mutant and complementary wild type subunits. Coexpression of both mutant subunits leads to an even more pronounced increase in basal signaling. In prior studies, it has been observed that ligand independent signaling could be induced by either (i) introduction of a disulfide bridge within the putative ligand binding pocket or (ii) coexpression of a wild type MOL 24463 8
MATERIALS AND METHODS
Cloning of the mouse R1 and R2 subunits. PCR primers were designed to amplify the open reading frame of each mouse GABA B R subunit (supplemental Table 1 ). As template for PCR, oligo-dT primed first strand cDNA was generated by reverse transcription of mouse brain mRNA. For PCR amplification, the following parameters were utilized: 30 cycles, each including denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 3 min. Following the last cycle, a final extension period of 10 min at 72°C was completed. Table 1 ) were designed to amplify two overlapping segments of cDNA encoding the R1 subunit (GenBank accession no. AF008649). The two resulting PCR products were then ligated using a unique Bsu36I site and subcloned into the expression vector pcDNA1.1 (Invitrogen, San Diego).
Primers (supplemental
An analogous strategy was used to amplify the R2 cDNA. In this case, the 5' primer (R2-A1 in supplemental Table 1 ) was designed from the mouse R2 genomic sequence which shares 100% identity with the corresponding 5' end of the rat R2 cDNA (GenBank accession no. AF074482). The 3' primer (R2-B2 in supplemental Table 1 ) was designed based on the untranslated region of the mouse gene. Internal primers (R2-A2 and R2-B1 in supplemental Table 1 ) hybridized to protein coding segments that are conserved between the mouse gene as well as the rat and human cDNAs. Following PCR amplification, two overlapping segments of cDNA, which together encode the complete R2 protein-coding region were ligated using a naturally occurring BamH1 site and then subcloned into pcDNA1.1.
The nucleotide sequence of the protein-coding region of each receptor cDNA was confirmed using automated DNA sequencing (model 373; Applied Biosystems, Foster City, CA). This article has not been copyedited and formatted. The final version may differ from this version. Generation of mutant receptors. R1 and R2 mutations were introduced into the corresponding cDNA using oligonucleotide-directed site-specific mutagenesis as previously described (Beinborn et al., 1993; Blaker et al., 1998) . The nucleotide sequence of the proteincoding region of each mutant receptor cDNA was confirmed using automated DNA sequencing.
Luciferase reporter gene assays. Human embryonic kidney (HEK293) cells were plated (5,000-7,000 per well) onto 96-well Primaria plates (BD Biosciences, Bedford, MA). After an overnight incubation, cells were transiently transfected with cDNAs encoding each of the following (unless otherwise noted): R1, R2, G q5i and an SRE 5x luciferase reporter gene construct.
As previously reported, G q5i enables G i/o coupled receptor activity to be detected using an SREluciferase reporter gene (Feuerbach et al., 2000; Hearn et al., 2002) . Transfections were done with lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. Twentyfour hours post-transfection, cells were incubated in serum-free Dubecco's modified Eagle's medium (Gibco, Carlsbad, CA) either in the absence (for determination of basal activity) or presence of ligand. After overnight stimulation, cells were lysed and luciferase activity was quantified using the LucLite luminescence reporter gene assay system (PerkinElmer, Boston, MA). GABA B R ligands that were studied included CGP54626, CGP52432, CGP55845, CGP35348 (Tocris Cookson Ltd, Bristol, United Kingdom) as well as baclofen and GABA (Sigma, St. Louis, MO).
Radioligand binding experiments.
Binding assays were performed as previously described (Lee et al., 1993) with minor modifications. COS-7 cells (10 6 /10 cm plate) were transfected using the DEAE dextran method with 5 µ g of each relevant GABA B R subunit cDNA. After ~16
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Cloning and functional assessment of the mouse R1 and R2 subunits. The cloned R1 sequence that we obtained by PCR is in full agreement with the previously reported cDNA (GenBank accession no. AF008649 and AF114168).
In addition to the R1 subunit, we cloned R2 using RT-PCR. Based on computational analysis of the corresponding gene, the mouse R2 cDNA sequence had been predicted to encode a 1455 amino acid protein (Genbank accession no. XM143750). In the current study, we have experimentally established that the actual cDNA encodes a 940 amino acid protein. The discrepancy between the computationally annotated and the cloned mouse R2 cDNA sequence can be attributed to mistaken inclusion of intron segments in the computationally predicted transcript. The cloned mouse R2 cDNA shows a high degree of conservation with other mammalian homologs. The encoded R2 protein is 99.6 % and 98 % identical to the rat and human R2 subunits, respectively (supplemental Fig. 1 ).
As with all known species homologs of this receptor, the mouse GABA B R functions as a heterodimer comprised of an R1 and an R2 subunit. GABA induced signaling was observed only in cells expressing both GABA B receptor subunits. In the absence of corresponding heterodimeric partners, basal activity of either the R1 or the R2 subunits approached zero. Of note, as reported for the rat homolog (Grunewald et al., 2002) , the wild type mouse GABA B R
shows an appreciable level of constitutive activity (Fig. 1) .
A single amino acid substitution in either R1 or R2 results in constitutive activity.
Within each class of GPCR (A, B, as well as C), naturally occurring activating mutations have This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) , the Y690V variant had the highest level of basal signaling and was therefore selected for further study ( Fig. 1, 2 ). It is of note that expression of R2 (Y690V) even in the absence of R1 showed a low yet detectable level of constitutive activity ( Fig. 1) . However, like the wild type R2 subunit, R2 (Y690V) in the absence of R1 does not respond to GABA.
Although targeted mutagenesis of R2 was successful in identifying a constitutively active variant, a parallel approach with the R1 subunit did not confer ligand independent signaling (Table 1) . Further mutagenesis of residues within the R1 VFTM revealed that a T290K substitution resulted in constitutive activity when the mutant was coexpressed with the wild type R2 subunit ( Fig.1, 2) . Replacement of T290 with Arg, another basic residue also led to an elevation in basal signaling. In contrast, substitution with Leu, a neutral residue, did not induce constitutive activity.
This article has not been copyedited and formatted. The final version may differ from this version. When the most active isoforms of each GABA B R subunit, R1 (T290K) and R2 (Y690V), were coexpressed, an even higher level of basal signaling was observed. Of note, despite the marked differences in constitutive activity among the wild type/mutant heterodimer combinations, the maximum level of GABA mediated signaling remained comparable (Fig. 1 ).
GABA and baclofen potency are increased at the constitutively active receptors. To explore the response of the constitutively active R1 and R2 mutants to agonists, HEK293 cells expressing different heterodimer combinations were stimulated with increasing concentrations of GABA or baclofen (Fig. 3, 4) . When either the R1 (T290K) or the R2 (Y690V) subunit was coexpressed with the complementary wild-type subunit, the mutant heterodimer showed a significantly lower EC50 for GABA versus the wild type value ( Table 2) . Similar potency shifts were observed using baclofen as the agonist. In addition, when both mutants R1 (T290K) and R2
(Y690V) were coexpressed, baclofen potency was further increased. Taken together, our results suggest a trend; increased basal activity is associated with higher agonist potency.
The high affinity putative antagonists CGP54626, CGP52432 and CGP55845 function as inverse agonists at the constitutively active receptors. Several compounds that were previously described as high affinity GABA B R antagonists were tested for activity on each of the constitutively active mutants (Fig. 3) . HEK 293 cells expressing combinations of wild type and/or constitutively active GABA B R mutant subunits were incubated with increasing concentrations of CGP54626, CGP52432 or CGP55845 (Fig. 5) . Each of these compounds attenuated basal signaling of the constitutively active receptors and was thus classified as an inverse agonist. We found a trend suggesting a reciprocal relationship between constitutive This article has not been copyedited and formatted. The final version may differ from this version. Table 2) .
CGP35348 shows partial agonist activity at the constitutively active GABA B receptors.
CGP35348 is described in the literature as a low affinity antagonist at the wild type GABA B R.
Using the luciferase reporter gene assay, assessment of this compound at the wild-type GABA B R revealed trace partial agonist activity. At the constitutively active GABA B R mutants the efficacy of CGP35348 was more readily detectable ( Fig 6) . As observed with GABA and baclofen, there was a trend toward higher potency of CGP35348 with increasing constitutive receptor activity ( Table 2 ). The increase in CGP35348 reached significance when assessed at the double mutant heterodimer, R1 (T290K)/R2 (Y690K).
Ligand binding assays with radiolabeled CGP54626. To evaluate the effect of the activating mutations on ligand affinities, we performed radioligand competition binding assays on COS-7 cells expressing either the wild type GABA B receptor (R1/R2) or one of three mutant heterodimers, R1/R2 (Y690V), R1 (T290K)/R2 or R1 (T290K)/R2 (Y690V) (Fig. 7) . The double mutant heterodimer showed a >100-fold increase in GABA affinity when compared with the wild type receptor. Expression of either R1 (T290K) or R2 (Y690V) with the complementary wild type subunit showed a 20-or a 12-fold increase in GABA affinity, 
DISCUSSION
The present study led to the novel observation that a single amino acid substitution in either of the two GABA B R subunits can result in agonist-independent signaling by a heterodimeric GPCR. The availability of these receptor constructs offers the opportunity to investigate agonist versus mutation-induced activation of a class C receptor. The GABA B R is of additional interest
given that this receptor is the prototype obligate heterodimer within the GPCR superfamily (Jones et al., 1998; Kaupmann et al., 1998; Kuner et al., 1999; White et al., 1998) and represents a key target for drug development in the therapeutic areas of human epilepsy, pain, and spasticity.
Much has been learned about GABA B R function by comparison with the related class C metabotropic glutamate receptor, mGluR1. Crystallographic studies of this homodimeric receptor revealed that the N-terminal extracellular region of each subunit includes a bilobate domain (VFTM) which is homologous to bacterial periplasmic proteins (Kunishima et al., 2000; O'Hara et al., 1993; Tsuchiya et al., 2002) . Current evidence from mutagenesis studies suggests that agonist stimulation triggers at least one bilobate domain to close. This appears to result in a conformational change in other parts of the receptor (i.e., the helical domain), which in turn activates G-proteins. The role of the VFTM, as first described for the mGluR1, is thought to be conserved in other class C GPCRs including the GABA B R.
We observed that a mutation in the GABA B R1 VFTM (T290K) resulted in constitutive activity that was appreciable only when this subunit was coexpressed with wild-type R2. This signaling through R2. Since R2 does not bind GABA, it would be anticipated based on current models, that a homologous mutation in the VFTM of the R2 subunit would not trigger constitutive activity. Consistent with this expectation, the corresponding mutation within the R2 subunit (N179K) did not induce ligand-independent signaling (see supplemental Fig.2 ).
Much has been learned about the ligand binding mechanism of class C receptors by comparison with the metabotropic glutamate receptor. The crystal structure of the glutamatebound form of mGluR1 revealed key residues at the interface of the two lobes of the VFTM that are involved in glutamate binding (Kunishima et al., 2000; O'Hara et al., 1993; Tsuchiya et al., 2002) . Current evidence suggests that agonist stimulation of mGlu1R triggers VFTM closure.
Among the residues that comprise the glutamate binding pocket is D208. Homology modeling suggests that the corresponding residue in the mouse GABA B R1 is A291 (Kniazeff et al., 2002) .
In our study, we demonstrate that mutation of the adjacent R1 amino acid, T290K, results in ligand independent signaling. We speculate that the positively charged lysine introduced in place of T290 interacts with one or more negatively charged residue(s) within or proximal to the putative ligand pocket, thereby inducing closure of the venus fly trap. This proposed mechanism is reminiscent of the previously reported constitutive receptor activation resulting from closure of the VFTM due to introduction of a disulfide bridge in this domain (Kniazeff et al., 2004) . In contrast to the constitutively active mutants described in the current study which maintain agonist responsiveness, covalent modification of the receptor abolished ligand induced function.
Mutation of the R2 subunit, Y690V also resulted in constitutive activity. The Y690V substitution is located at the transition between transmembrane domain VI and the third intracellular loop, a putative G protein binding domain . The location of this activating substitution raises the possibility that constitutive activity results from a mutation This article has not been copyedited and formatted. The final version may differ from this version. induced change in the interaction between GABA B R and the G-protein. In addition, our findings provide independent support for the postulated mechanism of GABA B R mediated signaling, in which G protein coupling occurs through the R2 subunit Havlickova et al., 2002; Robbins et al., 2001) . Consistent with this model, the homologous mutation in R1 (A803V) does not induce ligand independent signaling (see supplemental Fig. 2) .
In contrast to R1 (T290K) (which exhibits no activity in the absence of R2), the R2 variant, Y690V, shows a low level of constitutive activity even when expressed alone. This observation is in accordance with the established ability of R2 to independently reach the cell surface and confer G protein coupling (Binet et al., 2004; Pin et al., 2004) . Our finding that constitutive activity of R2 (Y690V) is greatly enhanced with coexpression of wild type R1 suggests that the latter subunit acts as a positive modulator of R2-mediated signaling, in addition to its wellestablished role as a GABA binding site. In fact, our observation provides independent support for the postulated role of R1 as an enhancer of R2 coupling efficiency. The concept that R1 acts as a modulator of R2 function was originally proposed to explain unexpected pharmacological properties of chimeric GABA B R heterodimers. These constructs were engineered to include only one type (either R1 or R2) of helical domain (Galvez et al., 2001; Knaizeff et al., 2004; Pin et al., 2004) . Study of these chimeric receptors demonstrated that absence of the R1 helical domain markedly reduced the efficacy and potency of GABA (Galvez et al., 2001 ). These findings, together with our observation that constitutive activity of a variant R2 is markedly enhanced by R1, suggest that GABA B R signaling, in the presence or absence of ligand is enabled by an interplay between the helical domains of both subunits.
In addition to the point mutations reported in this study, two other GABA B R modifications have been shown to result in ligand-independent signaling. In one report, it was demonstrated This article has not been copyedited and formatted. The final version may differ from this version. (Galvez et al., 2001; Pin et al., 2004) . A second report describes a constitutively active GABA B R heterodimer that resulted from introduction of two cysteine residues within the VFTM of R1 (Kniazeff et al., 2004) . These residues form a putative disulphide bridge, thus locking the binding domain in a closed position and triggering downstream signaling. Supporting this interpretation, constitutive activity can be inhibited by the reducing agent, DTT.
As opposed to the construct described above, constitutive activity of the mutant receptors, R1 Constitutively active class A receptors, when compared with corresponding wild type receptor proteins (i) show an increase in agonist potency and affinity (ii) distinguish inverse agonists from antagonists and (iii) have conserved antagonist affinity Samama et al., 1993; Tiberi and Caron, 1994) . Our results suggest that these features can be Table 2 ). These pharmacologic alterations were observed with point mutations in either GABA B R subunit when coexpressed with the complementary wild type subunit. In addition, coexpression of the two constitutively active subunits resulted in even more pronounced shifts when compared to the wild type heterodimer.
Another pharmacologic feature which broadly applies to constitutively active receptors is the ability to inhibit ligand-independent signaling with inverse agonists Samama et al., 1993; Tiberi and Caron, 1994 ). In the current study, we found that two structurally related compounds, CGP52432 and CGP55845, previously considered as neutral antagonists, inhibited basal signaling of the mutant GABA B R and should, thus, be classified as inverse agonists. In addition, using GABA B R mutants with significant basal activity, we were able to confirm the classification of CGP54626 as an inverse agonist. A previous report suggested that CGP54626 had inverse agonist activity when assessed at the rat wild type GABA B R (like the wild type mouse receptor, the rat homolog shows an appreciable level of This article has not been copyedited and formatted. The final version may differ from this version. ligand independent signaling) (Grunewald et al., 2002) . All three compounds (CGP54626, CGP52432 and CGP55845) share relatively high GABA B R binding affinity. It is of note that the potency of the three inverse agonists tends to decrease as the level of constitutive activity increases (i.e as a shift occurs from the inactive to active receptor state). This is consistent with current models in which the 'inactive' conformation is most favorable to inverse agonist interactions, whereas agonists preferentially bind the 'active' form of the receptor (Gether, 2000) .
Constitutively active mutants may be used to detect ligand activity that is not evident at the wild type receptor (Fig.6) . Once a ligand with intrinsic activity (i.e., an agonist or inverse agonist) is identified, it may be anticipated that structural modification can lead to the identification of full agonists. In an earlier manuscript, our group illustrated this strategy with the CCK-B receptor, a class A GPCR. Reminiscent of our current findings with the GABA B R, we showed that putative "antagonists" of the wild-type CCK receptor actually had significant partial or inverse agonist activity when tested on a constitutively active CCK-B receptor mutant.
Screening of a series of structural derivatives of these compounds led to the identification of molecules with near full agonist activity, both in vitro and in vivo (Kopin et al., 2003) . Based on these prior observations, it will be of interest to examine the activity of structural derivatives of the partial/inverse agonists identified using the constitutively active GABA B receptors. This approach provides a potential means to expedite the identification of novel, therapeutically useful GABA B R drugs.
This article has not been copyedited and formatted. The final version may differ from this version. Data represent the mean ± SEM from at least four independent experiments, each performed in triplicate (corresponding EC50 values are listed in Table 2 ). 'Basal' indicates the absence of ligand. Abbreviations: R1, GABA B R subunit 1; R2, GABA B R subunit 2. Table 2 ). 'Basal' indicates signaling in the absence of ligand. Abbreviations: R1, GABA B R subunit 1; R2, GABA B R subunit 2. 
